Single daily dose amikacin in paediatric patients with severe gram-negative infections.
Twenty-five children with serious Gram-negative infections were treated in a prospective study with amikacin 20 mg/kg administered in a single daily dose as a 30 min iv infusion for 4 to 12 days. In nine cases the amikacin was combined with beta-lactam antibiotics. Escherichia coli were the most frequent bacteria isolated followed by K. pneumoniae, Providencia and Enterobacter spp. and Pseudomonas aeruginosa with MICs ranging from 1 to 16 mg/l. Mean (+/- S.D.) peak and trough concentrations of days 1 and 4 of therapy ranged from 49 +/- 13.5 to 53.6 +/- 13.4 mg/l and 6 + 1.4 to 7.7 +/- 4.1 mg/l respectively. All patients were clinically and bacteriologically cured. No significant adverse reactions were observed. The results suggest that administration of a single daily dose of 20 mg/kg amikacin should be considered practical and safe in children. Further studies are needed.
Trujillo
H
H
Hospital Pablo Tobon Uribe, Medellin, Colombia.
Robledo
J
J
Robledo
C
C
Espinal
D
D
Garces
G
G
Mejia
J
J
Restrepo
C
C
Restrepo
F
F
Mejia de Rodriguez
G I
GI
Tamayo de Guitierrez
M C
MC
D000293:Adolescent; D000583:Amikacin / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D001424:Bacterial Infections / Q000188:drug therapy*; D002648:Child; D002675:Child, Preschool; D003404:Creatinine / Q000097:blood; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination / Q000008:administration & dosage / Q000627:therapeutic use; D004756:Enterobacteriaceae Infections / Q000188:drug therapy; D006801:Humans; D007223:Infant; D007769:Lactams; D011446:Prospective Studies; D011552:Pseudomonas Infections / Q000188:drug therapy
D000900:Anti-Bacterial Agents; D007769:Lactams; D000583:Amikacin; D003404:Creatinine